Abstract
October 5, 2018 and November 16, 2018 – Fluoroquinolones and quinolones are a class of broad-spectrum antibiotics that are active against bacteria of both Gram-negative and Grampositive classes. EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) reviewed the disabling and potentially permanent side effects with these medicines given by mouth, injection or inhalation. and recommended restricting their use. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on fluoro - quinolone and quinolone antibiotics in June 2018.
Visit the EMWA website
Search
Articles
Member Login
Links
Editoral Board
Editor-in-Chief
Co-Editors
Managing Editor
Victoria White
Deputy Managing Editor
Alicia Waltman
Associate Editors
Section Editors
Digital Communication
EMWA News
Gained in Translation
Getting Your Foot in the Door
Good Writing Practice
Alison McIntosh / Stephen Gilliver
In the Bookstores
Manuscript Writing
Medical Communications/Writing for Patients
Medical Devices
My First Medical Writing
News from the EMA
Out on Our Own
Pharmacovigilance
Regulatory Matters
Regulatory Public Disclosure
Teaching Medical Writing
The Crofter: Sustainable Communications
Jennifer Bell / Louisa Marcombes
Veterinary Writing
Editors Emeritus
Lay out Designer
Chris Monk